PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Both companies show declining cash positions (-2.60% vs AVXL's -2.64%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Similar yoy growth to AVXL's -2.64%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-2.19%
Below half of AVXL's -4.69%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.69%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
Higher Long-Term Investments Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Below half of AVXL's -4.69%. Michael Burry sees a potential red flag for stagnation or capital shortage.
28.73%
1.25-1.5x AVXL's 22.32%. Martin Whitman sees potential reliance on supplier financing. Verify liquidity.
27.69%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
-27.69%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
27.28%
Above 1.5x AVXL's 7.69%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of AVXL's -27.82%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.72%
50-75% of AVXL's 7.69%. Bruce Berkowitz notes a lower yoy liability increase.
4.00%
Higher Common Stock (Book Value) Growth compared to AVXL's zero value, indicating worse performance.
-3.83%
0.5-0.75x AVXL's -6.18%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
1.25-1.5x AVXL's -5.47%. Bruce Berkowitz notes an above-average equity expansion.
-2.25%
Below half AVXL's -4.69%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.67%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-0.77%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
2.64%
Similar yoy changes to AVXL's 2.64%. Walter Schloss sees parallel net leverage strategies.